c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3

Class

Multi-targeted receptor tyrosine kinase inhibitor

Pathway

anti-angiogenesis plus direct tumor cell apoptosis

Notes

original target text: c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3 (multi-target receptor tyrosine kinases)

This mechanism targets a family of receptor tyrosine kinases—c-Kit, VEGFR2, VEGFR3, FLT1 (VEGFR1), PDGFRβ, and FLT3—that sit on the surface of cells and, once activated by their respective growth factors, switch on internal signaling cascades that drive cell survival, proliferation, and the formation of new blood vessels. Blocking several of these kinases at once serves two complementary purposes: inhibiting VEGFR2, VEGFR3, and FLT1 starves a tumor by preventing angiogenesis, the process by which tumors recruit new blood supply, while inhibiting c-Kit and FLT3 can act more directly on tumor cells themselves, since many cancers depend on these receptors for growth signals. PDGFRβ inhibition adds a further anti-angiogenic layer by disrupting the supporting cells (pericytes) that stabilize new vessels. A single molecule engaging this combination is designed to attack tumor blood supply and tumor cell signaling simultaneously, which a narrower agent targeting only one pathway would not achieve. This broad mechanism is relevant across many solid tumor types and select hematologic malignancies where these kinases are overactive or mutated, making multi-targeted kinase inhibition a common general strategy in oncology drug design.